As shown in Fig. 4, the progression-free survival (PFS) of patients with late-stage NSCLC who received PD-1 inhibitors was analyzed based on multiple serum cytokine levels collected before immunotherapy. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.